|
|
|
|
|
terug |
Datum nieuwsfeit: 17-07-2008
( BW)(CA-GILEAD-SCIENCES)(GILD) Gilead Sciences Announces Second
Quarter 2008 Financial Results; Record Total Revenues of $1.28
Billion, Up 22 Percent over Second Quarter 2007; Record Product Sales
of $1.22 Billion, Up 34 Percent over Second Quarter 2007; Second
Quarter EPS of $0.46 per Share; Second Quarter Non-GAAP EPS of $0.49
per Share, Excluding Stock-based Compensation and Purchased In-Process
Research and Development Expenses
Business Editors/Health/Medical Writers
FOSTER CITY, Calif.--(BUSINESS WIRE)--July 17, 2008--Gilead
Sciences, Inc. (Nasdaq: GILD) announced today its results of
operations for the quarter ended June 30, 2008. Total revenues for the
second quarter of 2008 were $1.28 billion, up 22 percent compared to
total revenues of $1.05 billion for the second quarter of 2007. Net
income for the second quarter of 2008 was $442.8 million, or $0.46 per
diluted share, including after-tax stock-based compensation expense of
$26.4 million and after-tax purchased in-process research and
development (IPR&D) expense of $7.8 million. Excluding after-tax
stock-based compensation and IPR&D expenses of $34.2 million, non-GAAP
net income for the second quarter of 2008 was $477.0 million, or $0.49
per diluted share. Non-GAAP net income for the second quarter of 2007
was $442.2 million, or $0.46 per diluted share, which excluded
after-tax stock-based compensation expense of $34.3 million.
Product Sales
Product sales were a record $1.22 billion for the second quarter
of 2008, compared to $905.1 million in the second quarter of 2007, a
34 percent increase. This growth was driven primarily by Gilead's
antiviral franchise, including the strong growth of Atripla(R)
(efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate
300 mg) sales due primarily to the continued uptake of Atripla in the
United States and the recent launches in certain European countries,
as well as the continued growth of Truvada(R) (emtricitabine and
tenofovir disoproxil fumarate) sales in the United States and Europe.
Antiviral Franchise
Antiviral product sales were $1.12 billion in the second quarter
of 2008, a 34 percent increase from $837.4 million for the same period
in 2007. The increase was driven primarily by the sales volume growth
of Atripla and Truvada, as well as a favorable foreign currency
exchange impact.
-- Truvada
Truvada sales were $516.1 million for the second quarter of 2008,
an increase of 34 percent from $385.4 million in the second quarter of
2007. The increase in Truvada sales in the second quarter of 2008
compared to the same period of 2007 was driven primarily by sales
volume growth in the United States and Europe, and a favorable foreign
currency exchange impact.
-- Atripla
Atripla sales were $355.1 million for the second quarter of 2008,
an increase of 67 percent from $212.4 million in the second quarter of
2007. The increase in Atripla sales in the second quarter of 2008
compared to the same period in 2007 was driven primarily by the
continued uptake in the United States, as well as the recent launches
in certain European countries.
-- Viread
Viread(R) (tenofovir disoproxil fumarate) sales were $150.7
million for the second quarter of 2008, a three percent decrease from
$154.9 million in the second quarter of 2007. The decrease in Viread
sales in the second quarter of 2008 compared to the same period of
2007 was driven primarily by lower sales volumes in the United States
and Europe, partially offset by a favorable foreign currency exchange
impact.
-- Hepsera
Sales of Hepsera(R) (adefovir dipivoxil) for chronic hepatitis B
were $90.4 million for the second quarter of 2008, a 20 percent
increase from $75.2 million in the second quarter of 2007. The
increase in Hepsera sales in the second quarter of 2008 compared to
the same period of 2007 was driven primarily by a favorable foreign
currency exchange impact and sales volume growth in certain European
markets.
AmBisome
For the second quarter of 2008, sales of AmBisome(R) (amphotericin
B) liposome for injection for severe fungal infections were $69.8
million, an increase of eight percent from $64.8 million for the
second quarter of 2007. The increase in AmBisome sales in the second
quarter of 2008 compared to the same period of 2007 was driven
primarily by a favorable foreign currency exchange impact.
Royalty, Contract and Other Revenues
For the second quarter of 2008, royalty, contract and other
revenues resulting primarily from collaborations with corporate
partners were $60.9 million, a decrease of 57 percent from $143.0
million in the second quarter of 2007. The decrease in royalty,
contract and other revenues during the second quarter of 2008 compared
to the same period of 2007 was driven primarily by lower Tamiflu(R)
(oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of
$37.5 million in the second quarter of 2008 compared to Tamiflu
royalties of $123.1 million in the second quarter of 2007 due to
decreased sales related to pandemic planning initiatives worldwide.
Research and Development
Research and development (R&D) expenses in the second quarter of
2008 were $176.5 million compared to $135.9 million for the same
quarter in 2007. Non-GAAP R&D expenses, which exclude stock-based
compensation expense, for the second quarter of 2008 were $161.2
million, compared to $119.3 million for the same quarter in 2007.
Non-GAAP R&D expenses for the second quarter of 2008 were higher
primarily as a result of increased clinical study expenses as well as
higher headcount related to the growth in Gilead's business.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses in the second
quarter of 2008 were $219.5 million compared to $186.2 million for the
same quarter in 2007. Non-GAAP SG&A expenses, which exclude
stock-based compensation expense, for the second quarter of 2008 were
$200.9 million, compared to $157.7 million for the same quarter in
2007. Non-GAAP SG&A expenses for the second quarter of 2008 were
higher primarily as a result of increased marketing and promotional
expenses including those related to the launch of Atripla in certain
European countries, higher headcount related to the growth in Gilead's
business, as well as costs associated with certain termination-related
disputes in our international operations.
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on second quarter 2008
revenues and pre-tax earnings, which includes revenues and expenses
generated from outside the United States, was a favorable $45.2
million and $20.7 million, respectively, compared to the same period
in 2007.
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2008, Gilead had cash, cash equivalents and
marketable securities of $2.91 billion compared to $2.72 billion as of
December 31, 2007. For the first six months of 2008, Gilead generated
$1.00 billion of operating cash flows, which was partially offset by
Gilead's repurchases of $965.8 million of its common stock under its
share repurchase program.
Corporate Highlights
In April 2008, Gilead announced that Robin L. Washington joined
the company as Senior Vice President and Chief Financial Officer.
In May 2008, Gilead announced that John C. Martin, PhD was
appointed Chairman of the Board of Directors, and John F. Milligan,
PhD was appointed President. Dr. Martin is assuming the additional
role of Chairman of the Board from James M. Denny, who will remain a
member of Gilead's Board of Directors, serving as lead director. Mr.
Denny joined Gilead's Board in 1996 and was appointed Chairman in
2001. In addition to their new roles, Dr. Martin and Dr. Milligan will
continue to serve in their respective roles as Chief Executive Officer
and Chief Operating Officer.
Also in May 2008, Gilead and Navitas Assets, LLC (Navitas)
announced that the companies had entered into an agreement under which
Gilead acquired all of Navitas's assets related to its cicletanine
business. Gilead plans to evaluate cicletanine as a potential
treatment of pulmonary arterial hypertension (PAH).
In May and June 2008, the U.S. Patent & Trademark Office (PTO)
completed three of four reexamination proceedings and confirmed the
patentability of U.S. Patent No. 6,043,230, which covers a method of
use for Viread, and U.S. Patent Nos. 5,922,695 and 5,977,089, both of
which cover the composition of matter for Viread. In July 2008, the
PTO completed the final reexamination proceeding and confirmed the
patentability of U.S. Patent No. 5,935,946, which also covers the
composition of matter for Viread.
Product and Pipeline Highlights
Antiviral Franchise
In April 2008, Gilead announced the presentation of detailed
72-week data from two pivotal Phase III clinical trials, Studies 102
and 103, evaluating the safety and efficacy of once-daily Viread among
adult patients with chronic hepatitis B. These data were presented at
the 43rd Annual Meeting of the European Association for the Study of
the Liver in Milan, Italy in April 2008.
Also in April 2008, Gilead announced that the European Commission
granted marketing authorization for Viread for the treatment of
chronic hepatitis B in all 27 member states of the European Union.
Cardiovascular Franchise
In May 2008, Gilead announced the initiation of ATHENA-1, a Phase
IV, randomized, double-blind, placebo-controlled study evaluating
Letairis(R) (ambrisentan 5mg and 10mg tablets) in patients with PAH
demonstrating a sub-optimal response to sildenafil monotherapy.
Also in May 2008, Gilead announced results of a post-hoc analysis
of data collected during the ARIES-1, ARIES-2 and ARIES-E studies for
Letairis in PAH (WHO Group 1) patients with primarily WHO functional
class II or III symptoms. In addition, data from the pivotal Phase III
ARIES-1 and ARIES-2 studies of Letairis were published in the journal
Circulation.
Respiratory Franchise
In June 2008, Gilead announced results from an interim analysis of
12-month data from its open-label, Phase III AIR-CF3 study of
aztreonam lysine for inhalation, an investigational therapy in
development for the treatment of people with cystic fibrosis who have
pulmonary Pseudomonas aeruginosa infection. These data were presented
at the 31st Annual European Cystic Fibrosis Conference in Prague,
Czech Republic in June 2008.
Conference Call
At 4:30 p.m. Eastern Time today, Gilead will host a conference
call with a simultaneous webcast to discuss the results of its second
quarter of 2008. During this call/webcast, Gilead's management will
discuss the company's second quarter of 2008 results and provide a
general business update. The webcast will be available live via the
internet by accessing Gilead's website at www.gilead.com. To access
the webcast, please connect to the company's website at least 15
minutes prior to the conference call to ensure adequate time for any
software download that may be needed to hear the webcast.
Alternatively, please call 1-866-825-1709 (U.S.) or 1-617-213-8060
(international) and dial the participant passcode 39304842 to access
the call.
A replay of the webcast will be archived on the company's website
for one year, and a phone replay will be available approximately two
hours following the call through July 20, 2008. To access the phone
replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888
(international) and dial the participant passcode 84267247.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. Gilead's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia.
Non-GAAP Financial Information
Non-GAAP net income and net income per diluted share for the 2008
periods are presented excluding the after-tax impact of the IPR&D
expense incurred in connection with the acquisition of all of
Navitas's assets related to its cicletanine business, as well as the
after-tax impact of stock-based compensation expense and the related
methodology for computing dilutive securities for net income per
diluted share purposes. Non-GAAP net income and net income per diluted
share for the 2007 periods are presented excluding the after-tax
impact of stock-based compensation expense and the related methodology
for computing dilutive securities for net income per diluted share
purposes. Non-GAAP R&D expenses and SG&A expenses for the 2008 and
2007 periods are presented excluding the impact of stock-based
compensation expense. Management believes this non-GAAP information is
useful for investors, taken in conjunction with Gilead's GAAP
financial statements, because management uses such information
internally for its operating, budgeting and financial planning
purposes. Non-GAAP information is not prepared under a comprehensive
set of accounting rules and should only be used to supplement an
understanding of the company's operating results as reported under
United States generally accepted accounting principles.
Forward-looking Statements
Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Gilead cautions
readers that forward-looking statements are subject to certain risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include: Gilead's ability to
sustain growth in revenues for its antiviral and cardiovascular
franchises; unpredictable variability of Tamiflu royalties and the
strong relationship between this royalty revenue and global pandemic
planning and supply; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products; Gilead's
ability to successfully commercialize any products that receive
regulatory approvals; Gilead's ability to successfully develop its
respiratory and cardiovascular franchises; initiating and completing
clinical trials may take longer or cost more than expected; and other
risks identified from time to time in Gilead's reports filed with the
U.S. Securities and Exchange Commission. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," or the negative of those words or other comparable
words to be uncertain and forward-looking.
Gilead directs readers to its Annual Report on Form 10-K for the
year ended December 31, 2007, its Quarterly Report on Form 10-Q for
the first quarter of 2008 and its subsequent current reports on Form
8-K. Gilead claims the protection of the Safe Harbor contained in the
Private Securities Litigation Reform Act of 1995 for forward-looking
statements. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Truvada, Viread, Hepsera, AmBisome and Letairis are registered
trademarks of Gilead Sciences, Inc. Atripla is a registered trademark
of Bristol-Myers Squibb & Gilead Sciences, LLC. Tamiflu is a
registered trademark of F. Hoffmann-La Roche Ltd.
For more information on Gilead Sciences, Inc., please visit
www.gilead.com or call the Gilead Public Affairs Department at
1-800-GILEAD-5 (1-800-445-3235).
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
----------------------- -----------------------
2008 2007 2008 2007
----------- ---------- ----------- ----------
Revenues:
Product sales $1,217,216 $ 905,058 $2,358,522 $1,745,283
Royalty, contract
and other
revenues 60,909 143,031 177,755 331,236
----------- ----------- ----------- -----------
Total revenues 1,278,125 1,048,089 2,536,277 2,076,519
Costs and expenses:
Cost of goods sold
(1) 265,684 183,131 505,532 354,769
Research and
development (1) 176,542 135,931 331,843 266,021
Selling, general
and
administrative
(1) 219,533 186,179 414,490 352,737
Purchased in-
process research
and development
(2) 10,851 - 10,851 -
----------- ----------- ----------- -----------
Total costs and
expenses 672,610 505,241 1,262,716 973,527
----------- ----------- ----------- -----------
Income from
operations 605,515 542,848 1,273,561 1,102,992
Interest and other
income, net 14,026 27,689 36,726 50,793
Interest expense (3,174) (2,707) (6,279) (7,254)
Minority interest 2,160 2,401 4,035 4,554
----------- ----------- ----------- -----------
Income before
provision for income
taxes 618,527 570,231 1,308,043 1,151,085
Provision for income
taxes (1) 175,699 162,301 369,088 335,748
----------- ----------- ----------- -----------
Net income $ 442,828 $ 407,930 $ 938,955 $ 815,337
=========== =========== =========== ===========
Net income per share
- basic $ 0.48 $ 0.44 $ 1.01 $ 0.88
=========== =========== =========== ===========
Net income per share
- diluted $ 0.46 $ 0.42 $ 0.97 $ 0.85
=========== =========== =========== ===========
Shares used in per
share calculation -
basic 922,796 931,677 925,455 929,322
=========== =========== =========== ===========
Shares used in per
share calculation -
diluted 965,663 967,928 966,087 964,614
=========== =========== =========== ===========
Notes:
(1) The following is the stock-based compensation expense included in
the respective captions of the condensed consolidated statements
of income above:
Three Months Ended Six Months Ended
June 30, June 30,
----------------------- -----------------------
2008 2007 2008 2007
----------- ---------- ----------- ----------
Stock-based
compensation
expense:
Cost of goods
sold $ 2,848 $ 2,682 $ 4,542 $ 5,212
Research and
development 15,370 16,661 32,265 37,769
Selling, general
and
administrative 18,657 28,464 36,204 62,120
Income tax effect (10,466) (13,547) (20,601) (30,655)
----------- ----------- ----------- -----------
Total stock-
based
compensation
expense, net
of tax $ 26,409 $ 34,260 $ 52,410 $ 74,446
=========== =========== =========== ===========
(2) For the three and six months ended June 30, 2008, Gilead incurred
$10.9 million of purchased in-process research and development
expense as a result of the acquisition of all of Navitas Assets,
LLC's assets related to its cicletanine business.
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
(in thousands, except per share amounts)
Below is a reconciliation of Gilead's GAAP operating results and
diluted per share amounts as reported in the attached press release.
Non-GAAP net income and net income per diluted share for the 2008
periods are presented excluding the after-tax impact of the purchased
in-process research and development expense incurred in connection
with the acquisition of all of Navitas Assets, LLC's assets related
to its cicletanine business, as well as the after-tax impact of
stock-based compensation expense and the related methodology for
computing dilutive securities for net income per diluted share
purposes. Non-GAAP net income and net income per diluted share for
the 2007 periods are presented excluding the after-tax impact of
stock-based compensation expense and the related methodology for
computing dilutive securities for net income per diluted share
purposes. Non-GAAP R&D expenses and SG&A expenses for the 2008 and
2007 periods are presented excluding the impact of stock-based
compensation expense. Management believes this non-GAAP information
is useful for investors, taken in conjunction with Gilead's GAAP
financial statements, because management uses such information
internally for its operating, budgeting and financial planning
purposes. Non-GAAP information is not prepared under a comprehensive
set of accounting rules and should only be used to supplement an
understanding of the company's operating results as reported under
GAAP.
Three Months Ended Six Months Ended
June 30, June 30,
------------------ ------------------
2008 2007 2008 2007
-------- -------- -------- --------
Net income (GAAP) $442,828 $407,930 $938,955 $815,337
Stock-based compensation
expense, net of tax 26,409 34,260 52,410 74,446
Purchased in-process research
and development expense, net of
tax 7,769 - 7,769 -
-------- -------- -------- --------
Net income (Non-GAAP) $477,006 $442,190 $999,134 $889,783
======== ======== ======== ========
Shares used in per share
calculation - diluted (GAAP) 965,663 967,928 966,087 964,614
Dilutive securities 2,403 2,799 2,223 2,408
-------- -------- -------- --------
Shares used in per share
calculation - diluted (Non-
GAAP) 968,066 970,727 968,310 967,022
======== ======== ======== ========
Net income per share - diluted
(GAAP) $ 0.46 $ 0.42 $ 0.97 $ 0.85
======== ======== ======== ========
Net income per share - diluted
(Non-GAAP) $ 0.49 $ 0.46 $ 1.03 $ 0.92
======== ======== ======== ========
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
June 30, December 31,
2008 2007
------------- ------------
(unaudited) (Note 1)
Cash, cash equivalents and marketable
securities $ 2,908,352 $ 2,722,422
Other current assets 2,321,656 1,856,314
Property, plant and equipment, net 493,012 447,696
Other noncurrent assets 794,397 808,284
------------- ------------
Total assets $ 6,517,417 $ 5,834,716
============= ============
Current liabilities (2) $ 2,451,334 $ 736,275
Long-term liabilities and minority
interest (2) 293,858 1,638,451
Stockholders' equity 3,772,225 3,459,990
------------- ------------
Total liabilities and
stockholders' equity $ 6,517,417 $ 5,834,716
============= ============
Notes:
(1) Derived from audited consolidated financial statements at that
date.
(2) Convertible senior notes totalling $1.30 billion were reclassified
into current liabilities due to the exercisability of their
conversion feature for the three months ending September 30,
2008.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in thousands)
Three Months Ended Six Months Ended
June 30, June 30,
-------------------- ---------------------
2008 2007 2008 2007
---------- --------- ---------- ----------
(Note 1) (Note 1)
Antiviral products:
Truvada - U.S. $ 236,402 $ 186,256 $ 474,934 $ 373,044
Truvada - Europe 240,911 172,776 459,278 317,984
Truvada - Other
International 38,836 26,328 61,322 40,270
---------- --------- ---------- ----------
516,149 385,360 995,534 731,298
========== ========= ========== ==========
Atripla - U.S. 312,392 211,679 618,877 401,489
Atripla - Europe 37,504 - 51,699 -
Atripla - Other
International 5,205 705 8,742 1,078
---------- --------- ---------- ----------
355,101 212,384 679,318 402,567
========== ========= ========== ==========
Viread - U.S. 58,414 63,797 121,482 131,353
Viread - Europe 61,273 65,034 126,989 136,948
Viread - Other
International 30,994 26,066 54,877 47,274
---------- --------- ---------- ----------
150,681 154,897 303,348 315,575
========== ========= ========== ==========
Hepsera - U.S. 34,581 32,491 65,856 62,260
Hepsera - Europe 50,531 39,265 98,994 77,632
Hepsera - Other
International 5,253 3,417 8,537 6,625
---------- --------- ---------- ----------
90,365 75,173 173,387 146,517
========== ========= ========== ==========
Emtriva - U.S. 4,106 3,443 7,944 6,898
Emtriva - Europe 2,094 2,732 4,675 6,606
Emtriva - Other
International 1,888 3,429 3,858 4,423
---------- --------- ---------- ----------
8,088 9,604 16,477 17,927
========== ========= ========== ==========
Total Antiviral products
- U.S. 645,895 497,666 1,289,093 975,044
Total Antiviral products
- Europe 392,313 279,807 741,635 539,170
Total Antiviral products
- Other International 82,176 59,945 137,336 99,670
---------- --------- ---------- ----------
1,120,384 837,418 2,168,064 1,613,884
========== ========= ========== ==========
AmBisome 69,768 64,754 140,796 126,256
Letairis 24,686 113 45,023 113
Other products 2,378 2,773 4,639 5,030
---------- --------- ---------- ----------
96,832 67,640 190,458 131,399
========== ========= ========== ==========
---------- --------- ---------- ----------
Total product sales $1,217,216 $ 905,058 $2,358,522 $1,745,283
========== ========= ========== ==========
Note:
(1) Certain prior period amounts have been reclassified to conform to
current period presentation.
--30--
CONTACT: Gilead Sciences, Inc.
Robin Washington, 650-522-5688 (Investors)
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
Disclaimer: Deze bekendmaking is officieel geldend in de originele
brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten
worden vergeleken met de tekst in de brontaal welke als enige,
juridische geldigheid beoogt.